Commentary

Video

Dr Wilky on a Study of Botensilimab Plus Balstilimab in Refractory Metastatic Sarcoma

Author(s):

Breelyn Wilky, MD

Fact checked by:

Ashling Wahner Kristi Rosa
Conference|ESMO Congress

Breelyn Wilky, MD, discusses updated findings from a phase 1 study investigating botensilimab plus balstilimab in refractory metastatic sarcoma.

Breelyn Wilky, director, Sarcoma Medical Oncology, The Cheryl Bennett and McNeilly Family Endowed Chair in Sarcoma Research, deputy associate director, Clinical Research, associate professor, medicine, medical oncology, the University of Colorado Medicine, discusses updated findings from a phase 1 study (NCT03860272) investigating the combination of botensilimab (AGEN1181) and balstilimab (AGEN2034) in patients with refractory metastatic sarcoma.

Related Videos
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Guillermo Garcia-Manero, MD
Paolo Tarantino, MD
Rahul Banerjee, MD, FACP
Terence W. Friedlander, MD
Yuan Yuan, MD, PhD
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Related Content
Xinan Sheng, MD, of Peking University Cancer Hospital and Institute
September 17th 2024

Benmelstobart Plus Anlotinib Demonstrates Efficacy in Frontline Advanced RCC

D. Ross Camidge, MD, PhD; Natalie Vokes, MD
August 24th 2023

Camidge and Vokes Reflect on Research Journeys, Team Building, and Mentorship

Meredith McKean, MD, of Sarah Cannon Research Institute
September 16th 2024

Fianlimab/Cemiplimab Demonstrates Persistent Activity in Advanced Melanoma, Independent of LAG-3 and PD-L1 Status

Matthew Lunning, DO, FACP
July 24th 2023

Lunning and Kamdar Debate the Role of Pola-R-CHP in Treatment-Naïve DLBCL

Carlo B. Bifulco, MD, medical director of oncological molecular pathology and pathology informatics at the Providence Oregon Regional Laboratory and CMO of Providence Genomics
September 16th 2024

GigaPath AI Model May Predict Cancer Mutations, Tumor Mutation Burden in Lung, Other Cancers

Adrian Sacher, MD, a thoracic oncologist and affiliate scientist of Princess Margaret Cancer-Centre of the University of Toronto in Toronto, Ontario, Canada
September 16th 2024

AMG 193 Shows Preliminary Clinical Activity in MTAP-Deleted Solid Tumors